AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35624347 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to standard of care (SOC)
Number of subjects: 0
Study 36272026 — intervention group
Group type: EXPERIMENTAL
Intervention: SUBQ ravulizumab
Number of subjects: 136
Study 36272026 — intervention group
Group type: COMPARATOR
Intervention: IV ravulizumab
Number of subjects: 136
Study 33169203 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 5 mg
Number of subjects: 10
Study 33169203 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10 mg
Number of subjects: 10
Study 33169203 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 10
Study 33169203 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone + Alcohol
Number of subjects: 10
Study 32345936 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicenter trials in hand surgery
Number of subjects: 0
Study 32345936 — intervention group
Group type: COMPARATOR
Intervention: Single-center studies
Number of subjects: 0
Study 35667085 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,300mg TXA orally or 1,000mg TXA intravenously thrice daily for maximum 30 days
Number of subjects: 337
Study 33499902 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian target options
Number of subjects: 540
Study 33499902 — intervention group
Group type: COMPARATOR
Intervention: Meat target options
Number of subjects: 540
Study 32107929 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0
Study 32107929 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 0
Study 32107929 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab
Number of subjects: 0
Study 33355200 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 1001
Study 33355200 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1001
Study 33975645 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interdisciplinary intervention (10 weeks)
Number of subjects: 425
Study 33975645 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 425
Study 34226418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg atropine and 2 mg neostigmine
Number of subjects: 20
Study 34226418 — intervention group
Group type: COMPARATOR
Intervention: 2 mg/kg sugammadex
Number of subjects: 20
Study 35848152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional pressurized porous tantalum screws (PTS)
Number of subjects: 41
Study 35848152 — intervention group
Group type: COMPARATOR
Intervention: Cannulated compression screws (CCS)
Number of subjects: 41
Study 32816002 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment, with varying fluctuations in retinal thickness (measured by FCPT SD).
Number of subjects: 1731
Study 35148329 — intervention group
Group type: EXPERIMENTAL
Intervention: COTiD-UK (Community Occupational Therapy in Dementia-UK version)
Number of subjects: 468
Study 35148329 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 468
Study 34214863 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-disclosure questions
Number of subjects: 140
Study 34214863 — intervention group
Group type: COMPARATOR
Intervention: Low self-disclosure questions
Number of subjects: 140
Study 34214863 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-disclosure
Number of subjects: 140
Study 34214863 — intervention group
Group type: COMPARATOR
Intervention: Low self-disclosure
Number of subjects: 140
Study 35901401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based training (MBT)
Number of subjects: 61
Study 35901401 — intervention group
Group type: COMPARATOR
Intervention: Adaptive cognitive training (aCT)
Number of subjects: 61
Study 35901401 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 61
Study 33559354 — intervention group
Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0
Study 33559354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32289719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (bilateral primary motor cortex)
Number of subjects: 60
Study 32289719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (supplementary motor area)
Number of subjects: 60
Study 32289719 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 35288021 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus letrozole (2.5 mg oral letrozole twice daily for 5 days, with continuation of daily oestradiol)
Number of subjects: 112
Study 35288021 — intervention group
Group type: COMPARATOR
Intervention: HRT only (daily intramuscular progesterone plus daily oestradiol)
Number of subjects: 112
Study 32460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with a dose of 12 J/cm2 during 10 sessions
Number of subjects: 20
Study 32460396 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (laser turned off)
Number of subjects: 20
Study 32460396 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 20
Study 34183568 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 3 months
Number of subjects: 98
Study 34183568 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital routine care only)
Number of subjects: 98
Study 32121236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (VID, 2000 IU/day)
Number of subjects: 73
Study 32121236 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 long chain polyunsaturated fatty acids (OM, 722 mg/day docosahexaenoic acid)
Number of subjects: 73
Study 32121236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vitamin D and Omega-3 (VIDOM)
Number of subjects: 73
Study 32121236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 34008442 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch pump
Number of subjects: 278
Study 34008442 — intervention group
Group type: COMPARATOR
Intervention: Insulin pen
Number of subjects: 278
Study 33706870 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment (<120 mm Hg)
Number of subjects: 0
Study 33706870 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment (<140 mm Hg)
Number of subjects: 0
Study 32151822 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DAPT (12-24 months) in HBR patients
Number of subjects: 10081
Study 32151822 — intervention group
Group type: COMPARATOR
Intervention: Short DAPT (3-6 months) in HBR patients
Number of subjects: 10081
Study 32151822 — intervention group
Group type: EXPERIMENTAL
Intervention: Long DAPT (12-24 months) in non-HBR patients
Number of subjects: 10081
Study 32151822 — intervention group
Group type: COMPARATOR
Intervention: Short DAPT (3-6 months) in non-HBR patients
Number of subjects: 10081
Study 34145538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 28
Study 34145538 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 28
Study 32693116 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb navel plasters (Rheum officinale rhubarb powder)
Number of subjects: 374
Study 32693116 — intervention group
Group type: COMPARATOR
Intervention: Placebo flour stick
Number of subjects: 374
Study 36300825 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic diagnosis-guided transurethral resection of bladder tumour
Number of subjects: 538
Study 36300825 — intervention group
Group type: COMPARATOR
Intervention: White-light-guided transurethral resection of bladder tumour
Number of subjects: 538
Study 34289428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid high dosage
Number of subjects: 480
Study 34289428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid middle dosage
Number of subjects: 480
Study 34289428 — intervention group
Group type: EXPERIMENTAL
Intervention: Chai Hu oral liquid low dosage
Number of subjects: 480
Study 34289428 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieshu KangreSan (Positive control)
Number of subjects: 480
Study 34289428 — intervention group
Group type: COMPARATOR
Intervention: PBS (Control group)
Number of subjects: 480
Study 32398326 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary irradiation (specific doses not detailed)
Number of subjects: 437
Study 35647186 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil tablets
Number of subjects: 104
Study 35647186 — intervention group
Group type: COMPARATOR
Intervention: Control group (asprin)
Number of subjects: 104
Study 33784983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided parasternal intercostal nerve block with ropivacaine
Number of subjects: 41
Study 33784983 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study 32541498 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 0
Study 32541498 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid
Number of subjects: 0
Study 35216555 — intervention group
Group type: EXPERIMENTAL
Intervention: CFI-enhanced diagnostic procedure (n=134)
Number of subjects: 256
Study 35216555 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnostic procedures (Control group, n=122)
Number of subjects: 256
Study 34044869 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential implementation strategy (first centered on nurses, then involving physicians)
Number of subjects: 3273
Study 34044869 — intervention group
Group type: COMPARATOR
Intervention: Global implementation strategy (promoting cooperation of all health professionals from the beginning)
Number of subjects: 3273
Study 34044869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription of lifestyle change
Number of subjects: 3273
Study 35282830 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent responding screening during data collection
Number of subjects: 626
Study 35282830 — intervention group
Group type: COMPARATOR
Intervention: Participants screened in to the RCT
Number of subjects: 626
Study 35297768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention delivered via an existing service communication app for 10 weeks, including weekly push notifications and resources.
Number of subjects: 355
Study 35297768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health intervention (per-protocol analysis including only parents who downloaded the app).
Number of subjects: 355
Study 35297768 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group did not receive any intervention).
Number of subjects: 355
Study 32352803 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PCIT (5 days/week over 2 weeks)
Number of subjects: 60
Study 32352803 — intervention group
Group type: COMPARATOR
Intervention: Time-limited PCIT (1 day/week over 10 weeks)
Number of subjects: 60
Study 32352803 — intervention group
Group type: EXPERIMENTAL
Intervention: I-PCIT
Number of subjects: 60
Study 35466050 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (up to 360 mg/d)
Number of subjects: 126
Study 35466050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 34195864 — intervention group
Group type: EXPERIMENTAL
Intervention: ThrIVe-B intervention plus treatment as usual
Number of subjects: 43
Study 34195864 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control arm)
Number of subjects: 43
Study 35253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein
Number of subjects: 88
Study 35253279 — intervention group
Group type: EXPERIMENTAL
Intervention: Blends of milk and rapeseed protein (ratio 54:46 or 30:70)
Number of subjects: 88
Study 35253279 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study 32609001 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraverted presentation in public virtual environments
Number of subjects: 0
Study 32609001 — intervention group
Group type: EXPERIMENTAL
Intervention: Introverted presentation in public virtual environments
Number of subjects: 0
Study 32609001 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraverted presentation in private virtual environments
Number of subjects: 0
Study 32609001 — intervention group
Group type: EXPERIMENTAL
Intervention: Introverted presentation in private virtual environments
Number of subjects: 0
Study 36006772 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P63
Number of subjects: 24
Study 36006772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33469713 — intervention group
Group type: EXPERIMENTAL
Intervention: Home phototherapy
Number of subjects: 147
Study 33469713 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-hospital phototherapy
Number of subjects: 147
Study 35063267 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day + amlodipine 5 mg/day
Number of subjects: 94
Study 35063267 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg/day + cilnidipine 10 mg/day
Number of subjects: 94
Study 34807655 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sex groups with food response inhibition and attention training
Number of subjects: 261
Study 34807655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex groups with food response inhibition and attention training
Number of subjects: 261
Study 34807655 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-sex groups with generic response inhibition and attention training
Number of subjects: 261
Study 34807655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-sex groups with generic response inhibition and attention training
Number of subjects: 261
Study 32729404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (alpha2-agonist)
Number of subjects: 12
Study 32729404 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-antagonist)
Number of subjects: 12
Study 32729404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35969194 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training (IET) - wall squat, 3 times per week for 1 year
Number of subjects: 24
Study 35969194 — intervention group
Group type: COMPARATOR
Intervention: Control group - nonintervention
Number of subjects: 24
Study 33118429 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (5.7 g/d)
Number of subjects: 22
Study 33118429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isoproteic and caloric)
Number of subjects: 22
Study 32839253 — intervention group
Group type: COMPARATOR
Intervention: LIA with CACB
Number of subjects: 72
Study 32839253 — intervention group
Group type: EXPERIMENTAL
Intervention: iPACK block with LIA and CACB
Number of subjects: 72
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×/week AT + 2×/week active control (balance and tone, BAT)
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×/week RT + 2×/week active control (BAT)
Number of subjects: 216
Study 36085237 — intervention group
Group type: COMPARATOR
Intervention: 4×/week active control (BAT)
Number of subjects: 216
Study 36085237 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups will also be assessed for secondary outcomes including health-related quality of life, physical function, actigraphy measures, questionnaires, and falls.
Number of subjects: 216
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Penta E locus
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: TPOX locus
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed heterozygosity
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of discrimination (PD)
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Power of exclusion (PE)
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching probability (PM)
Number of subjects: 571
Study 32211958 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternity index (PI)
Number of subjects: 571
Study 33599993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (100% oxygen)
Number of subjects: 350
Study 33599993 — intervention group
Group type: COMPARATOR
Intervention: Tight-fitting facemask
Number of subjects: 350
Study 33599993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 350
Study 33153313 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote symptom monitoring intervention, delivered during daily automated coaching
Number of subjects: 358
Study 33153313 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 358
Study 35025558 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE (Concurrent Treatment of PTSD and SUD Using Prolonged Exposure)
Number of subjects: 81
Study 35025558 — intervention group
Group type: COMPARATOR
Intervention: Relapse Prevention (RP) therapy for SUD
Number of subjects: 81
Study 35538430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months health coaching, sit-stand desktop workstation, activity tracker (Fitbit), followed by 6 months text message support, then 6 months maintenance.
Number of subjects: 250
Study 35538430 — intervention group
Group type: COMPARATOR
Intervention: Delayed modified intervention after 12 months of usual care.
Number of subjects: 250
Study 33712987 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (30 mg twice daily)
Number of subjects: 84
Study 33712987 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (0.4 mg/kg/week orally)
Number of subjects: 84
Study 34802925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Number of subjects: 8
Study 34802925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of dexmedetomidine (0.1 mg kg–1) with midazolam (2 mg kg–1)
Number of subjects: 8
Study 34802925 — intervention group
Group type: COMPARATOR
Intervention: Intranasal administration
Number of subjects: 8
Study 34802925 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration
Number of subjects: 8
Study 34802925 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (IN and IM)
Number of subjects: 8
Study 33260183 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone combined with propofol (group OP)
Number of subjects: 193
Study 33260183 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl combined with propofol (group FP)
Number of subjects: 193
Study 35301878 — intervention group
Group type: EXPERIMENTAL
Intervention: UC + single general ward rehabilitation (SGR group)
Number of subjects: 0
Study 35301878 — intervention group
Group type: EXPERIMENTAL
Intervention: UC + general ward rehabilitation and intensive care unit (ICU) rehabilitation (IGR group)
Number of subjects: 0
Study 35301878 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC group)
Number of subjects: 0
Study 35301878 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 32110805 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 211
Study 32110805 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive tumor resection
Number of subjects: 211
Study 32110805 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of resection
Number of subjects: 211
Study 32110805 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + Radiotherapy
Number of subjects: 211
Study 32110805 — intervention group
Group type: COMPARATOR
Intervention: Surgery without Radiotherapy
Number of subjects: 211
Study 36136791 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced incentive (EI) condition, financial bonus based on performance improvement
Number of subjects: 38
Study 36136791 — intervention group
Group type: COMPARATOR
Intervention: Standard incentive (SI) condition, chance-based bonus
Number of subjects: 38
Study 34264835 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) group
Number of subjects: 347
Study 34264835 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant Treatment (AT) group
Number of subjects: 347
Study 35951209 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-CARE intervention
Number of subjects: 49
Study 35951209 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 49
Study 33879852 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology intervention (PPI), eight-session, telephone-delivered, completed by 12 participants (60% of those who started the intervention)
Number of subjects: 45
Study 32331886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish meal (FM)
Number of subjects: 8
Study 32331886 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood meal (BM)
Number of subjects: 8
Study 32331886 — intervention group
Group type: COMPARATOR
Intervention: Control (0% FM/BM)
Number of subjects: 8
Study 32331886 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels of FM or BM (33%, 67%, 100%)
Number of subjects: 8
Study 32331886 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (FM and BM)
Number of subjects: 8
Study 32331886 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual AA (Arginine, Ile, Met, Phe, His)
Number of subjects: 8
Study 35867199 — intervention group
Group type: EXPERIMENTAL
Intervention: Imeglimin (250–8000 mg single dose; 250–2000 mg twice daily multiple doses)
Number of subjects: 0
Study 35867199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34818391 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lip repositioning technique with periosteal sutures
Number of subjects: 12
Study 34818391 — intervention group
Group type: COMPARATOR
Intervention: Original LipStaT technique (Control)
Number of subjects: 12
Study 36193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg administered subcutaneously daily
Number of subjects: 136
Study 36193713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 36193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg
Number of subjects: 136
Study 34451039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-based gait retraining
Number of subjects: 71